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Background: Multi-morbidity, or the presence of multiple chronic diseases, is a major problem in clinical care and
is associated with worse outcomes. Additionally, the presence of mental health conditions, such as depression,
anxiety, etc., has further negative impact on clinical outcomes. However, most health systems are generally
configured for management of individual diseases instead of multi-morbidity. The study examined the prevalence
and differential impact of medical and psychiatric multi-morbidity on risk of death in adults with diabetes.
Methods: A national cohort of 625,903 veterans with type 2 diabetes was created by linking multiple patient and
administrative files from 2002 through 2006. The main outcome was time to death. Primary independent variables
were numbers of medical and psychiatric comorbidities over the study period. Covariates included age, gender,
race/ethnicity, marital status, area of residence, service connection, and geographic region. Cox regression was used
to model the association between time to death and multi-morbidity adjusting for relevant covariates.
Results: Hypertension (78%) and depression (13%) were the most prevalent medical and psychiatric comorbidities,
respectively; 23% had 3+ medical comorbidities, 3% had 2+ psychiatric comorbidities and 22% died. Among medical
comorbidities, mortality risk was highest in those with congestive heart failure (hazard ratio, HR = 1.92; 95% CI 1.89-1.95),
Lung disease (HR = 1.42; 95% CI 1.40-1.44) and cerebrovascular disease (HR = 1.39; 95% CI 1.37-1.40). Among psychiatric
comorbidities, mortality risk was highest in those with substance abuse (HR = 1.50; 95% CI 1.46-1.54), psychoses
(HR = 1.16; 95% CI 1.14-1.19) and depression (HR = 1.05; 95% CI 1.03-1.07). There was an interaction between medical
and psychiatric comorbidity (p = 0.003) so stratified analyses were performed. HRs for effect of 3+ medical comorbidity
(2.63, 2.66, 2.15) remained high across levels of psychiatric comorbidities (0, 1, 2+), respectively. HRs for effect of 2+
psychiatric comorbidity (1.69, 1.63, 1.42, 1.38) declined across levels of medical comorbidity (0, 1, 2, 3+), respectively.
Conclusions: Medical and psychiatric multi-morbidity are significant predictors of mortality among older adults
(veterans) with type 2 diabetes with a graded response as multimorbidity increases.
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Multi-morbidity, or the presence of multiple chronic
diseases, is a major problem in clinical care and is asso-
ciated with worse outcomes [1-3]. People with multi-
morbid conditions also have a higher medication burden
[4] and, not unexpectedly, have worse medication adher-
ence [5]. The prevalence of multi-morbidity is high (>50%)* Correspondence: egedel@musc.edu
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unless otherwise stated.in middle-aged and older populations [6]. However, most
health systems are generally configured for management of
individual diseases instead of multi-morbidity. A recent
review article suggests the number of studies testing inter-
ventions for patients with multi-morbid disease has
increased, but the findings showed that organizational in-
terventions with a broader focus and patient-specific in-
terventions not linked to care delivery had little impact
on health outcomes [7].
The presence of mental health conditions (e.g., depres-
sion, anxiety, etc.) in people with multi-morbidity has
adverse impact on clinical outcomes [8,9]. A study of
the impact of psychiatric conditions (depression/anxiety,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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tality among individuals with diabetes indicated that al-
cohol and drug abuse/dependence was associated with a
22% higher mortality [10]. Chronic conditions like dia-
betes tend to occur in clusters (with other cardiovascular
conditions like hypertension, heart disease and stroke)
[11]. However, very little is known about the separate
and combined impact of medical and psychiatric condi-
tions on mortality and which has the strongest impact
on risk of death in individuals with diabetes. Few studies
have carefully assessed the impact of both medical and
psychiatric multi-morbidity on mortality in middle-aged
and older adults with diabetes.
Older aged and elderly individuals have greater disease
burden and are more likely to have multimorbidity and
experience the adverse outcomes associated with multi-
morbidity. Because of the detailed clinical data available
in the Veterans Health Administration (VHA) databases,
the older age, and the ability to track patients over long
periods of time, veterans are an ideal population to tease
apart the impact of medical and psychiatric multi-
morbidity on mortality. However, the focus of this study
is to examine the impact of total burden of disease ra-
ther than specific comorbidities, so we used a national
sample of veterans with type 2 diabetes followed over 5
years to examine the prevalence and differential impact




A national cohort of veterans with type 2 diabetes was
created by linking multiple patient and administrative
files from the VHA National Patient Care and Pharmacy
Benefits Management (PBM) databases. We used a pre-
viously validated algorithm [12,13] for identifying vet-
erans with diabetes. Veterans were included in the
cohort if they had: 1) type 2 diabetes defined by two or
more International Classification of Diseases, Ninth Re-
vision (ICD-9) codes for diabetes (250, 357.2, 362.0, and
366.41) in the previous 24 months (2000 and 2001) and
during 2002 from inpatient stays and/or outpatient visits
on separate days (excluding codes from lab tests and
other non-clinician visits); or 2) prescriptions for insulin
or oral hypoglycemic agents (VA classes HS501 or
HS502, respectively; to capture those without a diabetes
ICD-9 code) in 2002. PBM data were available during the
entire period of analysis. When the data were merged
based on the criteria above, the total sample included
832,000 veterans. We excluded those not taking prescrip-
tion medications for diabetes (n = 201,255) and added
those who had one ICD-9 code for diabetes and prescrip-
tions filled in 2002 (n = 60,493); and 3,660 were excluded
due to death prior to 2002, missing age or no serviceconnection. The subset with complete data resulted in
a final cohort of 625,903 veterans. The Department of
Veterans Affairs maintains data through the VA Infor-
mation Resource Center (VIReC). Data was requested
from and approved for use by VIReC following data use
agreement requirements. The study was approved by the
Medical University of South Carolina Institutional Review
Board (IRB) and the Ralph H. Johnson Veterans Affairs
Medical Center Research and Development committee.
Outcome measure
The main outcome measure was time to death. Veterans
were followed from time of entry into the study until death,
loss to follow-up, or through December 2006. A subject
was considered censored if alive by December 2006.
Primary covariates
The primary covariates were medical comorbidity and
psychiatric comorbidity both defined as the count of dis-
eases for each subject throughout the study period. All
comorbidities were dichotomized as present or absent
where presence was determined by ICD-9 codes at entry
into the cohort based on a previously validated algorithm
in veterans [13]. Medical comorbidity variables included
anemia, cancer, cardiovascular disease (CVD), cerebrovas-
cular disease, congestive heart failure (CHF), fluid and
electrolyte disorders, hypertension, hypothyroidism, liver
disease, lung conditions (chronic pulmonary disease, pul-
monary circulation disease), obesity, peripheral vascular
disease, and other (acquired immunodeficiency syndrome–
AIDS, rheumatoid arthritis, renal failure, peptic ulcer dis-
ease and bleeding, weight loss). Psychiatric comorbidities
included psychoses, substance abuse (alcohol abuse, drug
abuse) and depression [13].
Demographic variables
We controlled for seven demographic variables. Age was
treated as continuous and centered at a mean of 66
years. Race/ethnicity included four categories with non-
Hispanic white (NHW) serving as the reference group.
Race/ethnicity was retrieved from the 2002 outpatient
and inpatient [Medical SAS] data sets. When missing or
unknown, the variable was supplemented using the in-
patient race1-race6 fields from the 2003 [Medical SAS]
data sets, the outpatient race1-race7 fields from the
2004 [Medical SAS] data sets, and the VA Vital Status
Centers for Medicare and Medicaid Services (CMS) field
for race. Gender, marital status, and location of resi-
dence (urban versus rural or highly rural) were dichot-
omous. Highly rural was categorized as rural according
to the VA definition of rurality [14]. Percentage service-
connectedness, representing the degree of disability due
to illness or injury that was aggravated by or incurred in
military service, was treated as dichotomous (1= > 50%,
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regions of the country, was treated as a categorical vari-
able: Northeast [VISNs 1, 2, 3], Mid-Atlantic [VISNs 4, 5,
6, 9, 10], South [VISNs 7, 8, 16, 17], Midwest [VISNs 11,
12, 15, 19, 23], and West [VISNs 18, 20, 21, 22] [15].
Statistical analysis
In preliminary analyses, crude associations were exam-
ined between mortality and all measured covariates using
chi-square tests for categorical variables and t-tests for
continuous variables. Cox regression methods were used
to model the association between time to death and
medical and psychiatric comorbidity after adjusting for
known covariates. Time to death was defined as the
number of months from time of entry into the cohort to
time of death or censoring (i.e., day last seen or May
2006). For the Cox model, appropriateness of the as-
sumption of proportionality was determined by testing
the coefficients of the interactions of time with the re-
spective covariate in multivariate analyses. Initially,
Cox models for each of the medical and psychiatric
comorbidities were fitted adjusting for all covariates
(race, socio-demographics). Then an interaction be-
tween medical and psychiatric comorbidity was tested
to check whether the association between mortality
and medical comorbidity was modified by the presence
of psychiatric comorbidity. HR estimates of medical
comorbidity for each level of psychiatric comorbidity
and estimates for levels of psychiatric comorbidity for
levels of medical comorbidity are reported since there
was significant interaction (p = 0.003). The Kaplan-Meier
method was used to plot the survival functions for both
medical and psychiatric comorbidities separately. Re-
sidual analysis was used to assess goodness-of-fit of each
of the models. All data analyses were conducted using
SAS 9.3 [16].
Results and discussion
The study population consisted of 625,903 veterans
with diabetes who were followed until death, loss to
follow-up, or through December 2006. The mean age
was 65.4 years (sd 11.1) with a range of 18–100 years.
Those with diabetes and no comorbid diagnosis com-
prised 10.6% of the sample. Hypertension was the
most common medical comorbidity (78.2%) and de-
pression was the most common psychiatric comorbid-
ity (12.7%). Over one fifth of the population (22.5%)
had three or more medical comorbidities and 3.2% of
the population had two or more psychiatric comorbid-
ities. During the follow-up period, 21.9% of individuals in
the cohort died. Table 1 shows demographic and comor-
bidity profile of the study population. The average sur-
vival time of those that died was 1.97 years. About one
quarter of deaths occurred in each of the first (25.8%)and second (26.2%) year of follow-up with 9.1% occurring
in the final year of follow-up.
The mortality risk associated with individual medical
and psychiatric comorbidities after adjusting for demo-
graphic factors (age, gender, race/ethnicity, marital status,
area of residence, service connection, and geographic
region) are presented in Table 2. Of the medical comor-
bidities examined, congestive heart failure, which was
present in 11.2% of the population, carried the greatest
mortality risk with patients with congestive heart failure
being almost twice as likely to die as those without con-
gestive heart failure (HR = 1.92). Lung and cerebrovascu-
lar disease present in 13.8% and 11.4%, respectively, of
the population also carried high mortality risk with pa-
tients with lung disease having 42% greater risk of mor-
tality than those without lung disease and patients with
cerebrovascular disease having 39% greater risk of mor-
tality than those without cerebrovascular disease. Alter-
natively, hypertension and obesity each carried a lower
mortality risk. For each of the psychiatric comorbidities
examined, depression, psychoses and substance abuse
carried significant mortality risk of 5%, 16% and 50%,
respectively.
Unadjusted Kaplan-Meier survival curves presented
in Figure 1, illustrate the effect of medical comorbidity
burden on probability of survival stratified by number
of psychiatric comorbidities (i.e., 0, 1 and 2). Within
each strata of psychiatric comorbidity burden, there
was a clear graded relationship between number of
medical comorbidities and probability of survival. Spe-
cifically, within each strata probability of survival was
highest in those with zero medical comorbidities and
lowest in those with 3 or more medical comorbidities.
In Figure 2, unadjusted Kaplan-Meier survival curves il-
lustrate the effect of psychiatric comorbidity burden on
probability of survival stratified by number of medical co-
morbidities (i.e., 0, 1, 2 and 3 or more). In contrast to dif-
ferent survival curves for each level of comorbidity,
Figure 2 illustrates a similar probability of survival across
levels of psychiatric comorbidity burden in veterans with
zero and 1 medical comorbidity. Moreover, while there is
some differentiation in survival across levels of psychi-
atric comorbidity burden in veterans with 2 and 3 or
more medical comorbidities, survival probability did not
clearly decrease with increased psychiatric comorbidity
burden.
Table 3 shows the HR and corresponding 95% CI for
the association between number of medical comorbidi-
ties (i.e., 0, 1, 2 and 3 or more) and mortality stratified
by number of psychiatric comorbidities (i.e., 0, 1 and 2)
after adjusting for demographic factors (age, gender,
race/ethnicity, marital status, area of residence, service
connection, and geographic region). The mortality haz-
ards associated with having 2 or 3 or more medical








Age (years; mean, sd) 65 (11.1) 64 (10.9) 71 (9.8)
Male 97.8 97.5 98.7
Race/Ethnicity
Non-Hispanic Black 72.1 69.9 79.8
Non-Hispanic White 13.2 13.5 12.3
Hispanic 5.3 5.5 4.6
Other/Unknown race 9.4 11.1 3.3
Married 65.3 66.1 62.3
Area of Residence
Rural 36.8 36.7 37
Urban 61.7 61.8 61.6
Highly rural 1.5 1.5 1.4
Service Connection <50% 87.7 87.8 87.6
Geographic Region
Northeast 11.0 11.0 11.1
Mid-Atlantic 21.7 21.6 21.9
South 21.1 21.0 21.5
Mid-West 30.9 31.0 30.7
West 15.3 15.4 14.8
Medical Comorbidity
Hypertension 78.2 77.4 81.2
Lung disease 13.8 11.2 23.0
Obesity 12.9 13.6 10.2
Peripheral vascular disease 11.9 9.4 20.8
Cerebrovascular disease 11.4 9.1 19.7
Congestive heart failure 11.2 7.4 24.5
Anemia 7.5 5.6 14.0
Cancer 7.3 5.6 12.6
Hypothyroidism 6.2 5.8 7.5
Fluid/electrolyte disorders 4.9 3.6 9.6
Other disease 3.7 2.8 6.6
Cardiovascular disease 3.6 2.7 6.8
Liver disease 3.1 2.5 5.5
Psychiatric Comorbidities
Depression 12.7 12.5 13.6
Psychoses 4.4 4.2 5.1
Substance abuse 3.9 3.7 4.5
Medical Comorbidities
0 Medical comorbidity 12.1 13.8 6.4
1 Medical comorbidity 38.1 41.8 24.8
2 Medical comorbidities 27.3 27.1 27.9
3+ Medical comorbidities 22.5 17.3 40.9
Psychiatric Comorbidities
Table 1 Demographic and Comorbidity Profile of
Veterans* (Continued)
0 Psychiatric comorbidity 82.8 83.4 80.8
1 Psychiatric comorbidity 14.0 13.5 15.8
2+ Psychiatric comorbidities 3.2 3.1 3.4
Total Comorbidities
1 Comorbidity 34.0 37.3 22.0
2 Comorbidities 27.2 27.5 26.1
3 Comorbidities 14.9 13.6 19.7
4 Comorbidities 7.4 5.9 12.6
5+ Comorbidities 6.0 3.8 13.9
*All numbers represent percentages unless otherwise indicated.
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were 1.54 and 2.63, respectively, in veterans with diabetes
without any psychiatric comorbidity. Similar patterns in
mortality hazards were seen in veterans with a single
psychiatric comorbidity among those with 2 or 3 or
more medical comorbidities compared to those with
no medical comorbidities (HRs of 1.51 and 2.66, re-
spectively). The difference in mortality hazard among
those with greater medical comorbidity decreased only
slightly in veterans with two psychiatric comorbiditiesTable 2 Hazard Ratio and 95% Confidence Interval
Estimates for Each Disease Category* (ordered by
decreasing level of risk)
HR (95% CI)
Medical Comorbidities
Congestive heart failure 1.92 (1.89, 1.95)
Liver disease 1.61 (1.57, 1.65)
Lung disease 1.42 (1.40, 1.44)
Cerebrovascular disease 1.39 (1.37, 1.40)
Cancer 1.38 (1.36, 1.40)
Other diseases 1.38 (1.35, 1.41)
Peripheral vascular disease 1.35 (1.33, 1.37)
Fluid/electrolyte disorders 1.33 (1.30, 1.36)
Anemia 1.25 (1.23, 1.27)
Cardiovascular disease 1.16 (1.13, 1.18)
Hypothyroidism 0.99 (0.97, 1.01)
Hypertension 0.91 (0.90, 0.92)
Obesity 0.88 (0.86, 0.90)
Psychiatric Comorbidities
Substance abuse 1.50 (1.46, 1.54)
Psychoses 1.16 (1.14, 1.19)
Depression 1.05 (1.03, 1.07)
*Adjusted for sociodemographic characteristics including age, gender,
race/ethnicity, marital status, area of residence, service connection, and
geographic region.
Figure 1 Unadjusted Kaplan-Meier Survival Curves for Medical
Comorbidity at Each Level of Psychiatric Comorbidity.
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ity (HR 2.15), respectively.
Additionally, Table 3 shows the HR and corresponding
95% confidence intervals (CI) for the association between
number of psychiatric comorbidities (i.e., 0, 1 and 2) and
mortality stratified by number of medical comorbidities
(i.e., 0, 1, 2 and 3 or more) after adjusting for demographic
factors. The mortality hazard associated with having a
single as compared to zero psychiatric comorbidities
remained constant across all medical comorbidity categor-
ies with respective hazard ratios of 1.23 and 1.24 in vet-
erans with zero and 3 or more medical comorbidities. In
contrast, the mortality hazard associated with having two
as compared to zero psychiatric comorbidities decreasedfrom 1.69 in veterans with zero medical comorbidities to
1.38 in veterans with 3 or more medical comorbidities.
Conclusions
The findings of this study clearly demonstrate that the
total burden of medical and psychiatric multi-morbidity
are significant predictors of mortality among middle age
and older adults (veterans) with type 2 diabetes with a
graded response as medical multimorbidity increases.
The average survival time was about 2 years with 52% of
deaths occurring in the first 2 years of follow-up and 9%
in the final year of follow-up. Among medical comorbid-
ities, mortality risk was highest in those with congestive
heart failure, lung disease and cerebrovascular disease;
while among psychiatric comorbidities, mortality risk
was highest in those with substance abuse, psychoses
and depression. There was an interaction between med-
ical and psychiatric comorbidity indicating that the asso-
ciation between mortality and medical comorbidity was
modified by the presence of psychiatric comorbidity so
stratified analyses were performed. HRs for effect of 3+
medical comorbidities remained high across levels of
psychiatric comorbidities (0, 1, 2+), while HRs for effect
of 2+ psychiatric comorbidities declined across levels of
medical comorbidity (0, 1, 2, 3+).
Interestingly, comorbid hypertension and obesity were
associated with lower mortality risk in this sample of
veterans with type 2 diabetes. Since more than two-
thirds of obese veterans also have comorbid hyper-
tension [17], it is likely that the reduced mortality risk
associated with hypertension was demonstrated among
obese veterans. These findings may be explained by
multiple interventions within the VA system from 2000–
2010 (encompasses the time period of this study) that were
successful in achieving blood pressure control among
veterans who are provided access to healthcare services
and to a very affordable formulary of anti-hypertensive
medications [18]. Furthermore, one should consider
that this analysis examined data generated shortly after
diabetes was designated as a CVD risk equivalent along
with tobacco smoking, hypertension, and hyperlipidemia
[19]. In that case, it is likely that a strong awareness of
CVD as a leading cause of death, growing evidence
of behavioral management and treatment effectiveness
from multiple large-scale RCTs (like Hypertension Opti-
mal Treatment (HOT), United Kingdom Prospective
Diabetes Study (UKPDS), Diabetes Prevention Program
(DPP), Action to Control Cardiovascular Risk in Diabetes
(ACCORD), and Antihypertensive and Lipid Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT), to
name a few), and broad public health efforts lead by
guidelines from several national organizations (American
Heart Association (AHA), American Diabetes Association
(ADA), and National Heart, Lung, and Blood Institute
Figure 2 Unadjusted Kaplan-Meier Survival Curves for Psychiatric Comorbidity at Each Level of Medical Comorbidity.
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people with diabetes not only reduced CVD mortality
rates, but also helped to reduce the impact of comor-
bid hypertension and obesity on mortality in people with
diabetes.
Medical comorbidities exerted the greatest influence
on mortality and had significantly stronger effects on
hazard of death compared to psychiatric comorbidities.
In stratified analyses, the risk of death with increasing
medical comorbidity remained high across each level of
psychiatric comorbidity with the greatest risk seen in
individuals with 3+ medical comorbidities (HR ranged
2.15-2.66) compared to no psychiatric comorbidity. In
contrast, risk of death with increasing psychiatric comor-
bidity was not consistently high across levels of medical
comorbidities. Instead the risk of death with 2+ psychi-
atric comorbidities declined as the number of medical
comorbidities increased. In other words, among those
with 2 or more psychiatric comorbidities, baseline risk
(no medical comorbidity) is higher while the risk as-
sociated with additional medical comorbidity is lower.
One explanation could be increased care associated
with multiple medical and psychiatric comorbidities.
However, the mortality risk from psychiatric comor-
bidities remained significant, emphasizing the need forgreater attention to identifying and treating psychiatric
comorbidities, instead of focusing on medical comorbidi-
ties alone.
There is growing awareness of the burden of multi-
morbidity and the need to develop new treatment
paradigms that account for multi-morbidity. This is par-
ticularly important for certain populations such as the
elderly, veterans and low income and ethnic minorities
with diabetes, where the prevalence of multi-morbidity is
high and the risk for adverse outcomes increase exponen-
tially with increasing levels of multi-morbidity [20-22].
The current approach to treatment for diabetes that is fo-
cused on single or related disease (e.g. diabetes and
CVD) management may no longer be appropriate based
on emerging evidence of the high prevalence of multi-
morbidity and its detrimental effect on health outcomes
including polypharmacy, increased morbidity, disability,
health utilization/cost and mortality [5,7,23-26]. As the
paradigm of care shifts to patient-centered care, strat-
egies are needed to treat the individual as a whole and
coordinate care while accounting for medical and psychi-
atric multi-morbidity. This will be particularly important
in middle age and older adults, where our findings
show that multi-morbidity is associated with signifi-
cant increases in mortality. Newer evidence suggests that
Table 3 Hazard Ratios (HR)* and 95% confidence Interval
(CI) for Effect of Medical and Psychiatric Comorbidity
Burden on Mortality among Veterans with Diabetes
HR (95% CI)
0 Psychiatric Comorbiditiesa
0 Medical Comorbidity 1.00
1 Medical Comorbidity 1.05 (1.03, 1.08)
2 Medical Comorbidities 1.54 (1.51, 1.58)
3+ Medical Comorbidities 2.63 (2.57, 2.70)
1 Psychiatric Comorbiditya
0 Medical Comorbidity 1.00
1 Medical Comorbidity 1.06 (0.98, 1.14)
2 Medical Comorbidities 1.51 (1.41, 1.63)
3+ Medical Comorbidities 2.66 (2.49, 2.85)
2 Psychiatric Comorbiditiesa
0 Medical Comorbidity 1.00
1 Medical Comorbidity 1.02 (0.87, 1.19)
2 Medical Comorbidities 1.30 (1.12, 1.52)
3+ Medical Comorbidities 2.15 (1.86, 2.48)
0 Medical Comorbiditiesb
0 Psychiatric Comorbidity 1.00
1 Psychiatric Comorbidity 1.23 (1.14, 1.32)
2+ Psychiatric Comorbidities 1.69 (1.47, 1.94)
1 Medical Comorbidityb
0 Psychiatric Comorbidity 1.00
1 Psychiatric Comorbidity 1.23 (1.19, 1.27)
2+ Psychiatric Comorbidities 1.63 (1.52, 1.75)
2 Medical Comorbiditiesb
0 Psychiatric Comorbidity 1.00
1 Psychiatric Comorbidity 1.20 (1.17, 1.24)
2+ Psychiatric Comorbidities 1.42 (1.34, 1.51)
3 Medical Comorbiditiesb
0 Psychiatric Comorbidity 1.00
1 Psychiatric Comorbidity 1.24 (1.22, 1.27)
2+ Psychiatric Comorbidities 1.38 (1.32, 1.43)
*Interaction terms were used to determine adjusted hazard ratios for the
effect of medical comorbidity within strata of psychiatric comorbiditya as well
as for the effect of psychiatric comorbidity within strata of medical
comorbidityb. Adjusted for sociodemographic characteristics including age,
gender, race/ethnicity, marital status, area of residence, service connection,
and geographic region.
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cific patient needs (e.g., medication management or
functional status) are effective for improving outcomes
among patients with multi-morbidity [7]. Our findings fur-
ther highlight the need to integrate care for medical and
psychiatric conditions and address the fragmentation of
health care that currently exists with separate coverages
for medical and mental health conditions. Some of thestrategies will require policy change in how mental health
services are covered and reimbursement structure in pri-
mary care settings.
Strengths of our study include the study population,
its longitudinal design with 5 years of follow-up data,
the extensive data available on comorbidities, and our
ability to identify racial/ethnic group in over 90% of the
cohort. To place this study in context, we report on the
limitations. First, the VA medical record either omits or
fails to update many important social, environmental and
behavioral variables including socio-economic status,
diet, physical activity, weight and alcohol consumption,
as well as disease measures such as diabetes duration.
Second, there is no way to account for the lag time be-
tween disease onset and diagnosis; thus, the timing of on-
set of comorbidity cannot be accurately determined in
this retrospective cohort analysis. Finally, there were no
measures of disease control accounted for so the findings
are generalizable to those veterans with the diagnoses in-
cluded in this study.
Nevertheless, our findings are important and show
that, in this national longitudinal cohort of veterans with
diabetes followed over 5 years, multi-morbidity was as-
sociated with increased risk of death and the risk of
death was incremental with a graded response in mortal-
ity risk with increasing numbers of medical and psychi-
atric comorbidities.Competing interests
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